EULAV Asset Management Raises Position in Medpace Holdings, Inc. $MEDP

EULAV Asset Management boosted its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 47.1% during the 3rd quarter, Holdings Channel.com reports. The firm owned 32,511 shares of the company’s stock after purchasing an additional 10,406 shares during the period. EULAV Asset Management’s holdings in Medpace were worth $16,716,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of MEDP. Clarkston Capital Partners LLC bought a new stake in shares of Medpace in the second quarter valued at $40,569,000. Brighton Jones LLC grew its stake in shares of Medpace by 160.4% during the 3rd quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock worth $2,087,000 after acquiring an additional 2,501 shares during the period. Jump Financial LLC purchased a new stake in Medpace in the 2nd quarter worth about $15,729,000. Annex Advisory Services LLC raised its stake in Medpace by 6.6% in the 3rd quarter. Annex Advisory Services LLC now owns 101,685 shares of the company’s stock valued at $52,282,000 after acquiring an additional 6,264 shares during the period. Finally, Arkadios Wealth Advisors bought a new stake in Medpace in the 2nd quarter valued at about $327,000. 77.98% of the stock is owned by institutional investors.

Insider Activity at Medpace

In other Medpace news, CFO Kevin M. Brady sold 3,000 shares of the firm’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $590.35, for a total value of $1,771,050.00. Following the sale, the chief financial officer owned 6,000 shares of the company’s stock, valued at $3,542,100. This trade represents a 33.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO August J. Troendle sold 668 shares of Medpace stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total value of $394,580.92. Following the sale, the chief executive officer owned 646,184 shares of the company’s stock, valued at approximately $381,694,426.96. This trade represents a 0.10% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 387,925 shares of company stock valued at $233,386,647. Company insiders own 20.30% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on MEDP shares. Mizuho set a $660.00 target price on shares of Medpace in a research report on Friday, January 9th. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. Cowen reaffirmed a “sell” rating on shares of Medpace in a report on Friday, October 24th. BMO Capital Markets initiated coverage on shares of Medpace in a report on Thursday, November 13th. They set a “market perform” rating and a $600.00 target price on the stock. Finally, TD Cowen increased their target price on Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a research report on Friday, October 24th. Two analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $491.27.

Medpace Trading Up 0.3%

Shares of NASDAQ:MEDP opened at $618.04 on Friday. The company has a 50 day moving average of $582.30 and a 200 day moving average of $507.97. The stock has a market cap of $17.41 billion, a P/E ratio of 43.22, a P/E/G ratio of 2.07 and a beta of 1.43. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $626.26.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business had revenue of $659.90 million for the quarter, compared to analysts’ expectations of $640.49 million. During the same period in the prior year, the company posted $3.01 EPS. The business’s revenue for the quarter was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, equities analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.